Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and life-threatening genetic disorders. Headquartered in Cambridge, Massachusetts, Spyre leverages adeno-associated virus (AAV) vector technology to deliver functional copies of genes to target tissues. The company’s research is centered on indications with high unmet medical need in renal and hepatic diseases, aiming to restore normal protein function and halt disease progression at the molecular level.
Spyre’s lead program is directed toward autosomal recessive polycystic kidney disease (ARPKD), a severe congenital disorder characterized by progressive kidney enlargement and hepatic fibrosis. In preclinical studies, Spyre’s proprietary AAV platform has demonstrated efficient transduction of renal epithelial cells, leading to restoration of the defective gene’s activity. Parallel efforts include a second candidate for citrin deficiency, an inherited urea cycle disorder that causes life-threatening liver dysfunction in infants and children.
Underpinning these programs is Spyre’s modular AAV vector design, which enables tissue-selective delivery and scalable manufacturing. The company has established a fully integrated process from vector development to clinical-grade production, supported by partnerships with leading contract development and manufacturing organizations (CDMOs). Spyre’s approach emphasizes precision dosing and long-term expression, with the goal of achieving durable clinical benefit from a single administration.
Founded in 2018 by veterans of the gene therapy field, Spyre Therapeutics is led by Chief Executive Officer Dr. Emily Foster, who has over 20 years of experience in rare disease drug development. The executive team and board include experts in gene therapy, regulatory affairs, and translational research. Spyre maintains collaborations with academic institutions and patient advocacy groups in North America and Europe, positioning the company to advance its pipeline into human clinical trials and bring transformative treatments to underserved patient populations.
AI Generated. May Contain Errors.
